Autoimmune diseases

Researchers in the UK have utilised precision gene editing to identify a regulatory element concealed within a gene associated with several autoimmune...

Allogene's Dual-Acting CAR T Candidate ALLO-329...

CMN Clinical

Jan. 29, 2025

The FDA has cleared Allogene Therapeutics' IND application for ALLO-329, a novel dual-targeting CAR T cell therapy designed to treat multiple...

Autoimmune diseases

Refractory Systemic Lupus Erythematosus, SLE, (NCT07083349)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Multiple Sclerosis, (NCT07008378)
Sponsors:
Genentech, Inc.

IND Enabling

Phase I

Phase II

Phase III

Refractory Autoimmune Disease, (NCT06925542)
Sponsors:
CRISPR Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Systemic Lupus Erythematosus, SLE, (NCT06752876)
Sponsors:
Caribou Biosciences, Inc.

IND Enabling

Phase I

Phase II

Phase III

Lupus Nephritis, (NCT06681337)
Sponsors:
Bioray Laboratories

IND Enabling

Phase I

Phase II

Phase III

Neuromyelitis Optica Spectrum Disease, NMOSD, (NCT06633042)
Sponsors:
Bioray Laboratories

IND Enabling

Phase I

Phase II

Phase III

Systemic Lupus Erythematosus, SLE, (NCT06373991)
Sponsors:
EdiGene Inc.

IND Enabling

Phase I

Phase II

Phase III

Refractory Autoimmune Diseases, (NCT06485232)
Sponsors:
Xuanwu Hospital, Beijing

IND Enabling

Phase I

Phase II

Phase III